Stoke Therapeutics

84 articles with Stoke Therapeutics

• 

  Investors Continue to Fund Data Over Ideas In Current Biotech Downturn

  8/17/2022

  BioSpace spoke with industry executives and investors about the current economic situation in the biotech industry and sourced tips on how leaders can weather the downturn.

• Stoke Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

  8/8/2022

  Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, reported financial results for the second quarter of 2022 and provided business updates.

• Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

  6/1/2022

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:00 p.m. ET.

• Stoke Therapeutics Reported First Quarter Financial Results and Provides Business Updates

  5/10/2022

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2022 and provided business updates.

• Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

  5/2/2022

  Stoke Therapeutics, Inc. (Nasdaq: STOK), today announced new preclinical data that demonstrated dose-related target engagement and increases in OPA1 protein levels in retinal tissue of non-human primates (NHPs) following intravitreal (IVT) administration of STK-002.

• Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

  4/7/2022

  Stoke Therapeutics, Inc. announced today the upcoming presentation of new preclinical data on STK-002 at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting being held May 1-4, 2022 in Denver, Colorado.

• Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/5/2022

  Stoke Therapeutics, Inc. today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m. ET.

• Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

  3/10/2022

  Stoke Therapeutics, Inc. today reported financial results for the full year ended December 31, 2021 and provided business updates.

• Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

  2/28/2022

  Stoke Therapeutics, Inc. announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

• Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

  1/10/2022

  Acadia Pharmaceuticals and Stoke Therapeutics, Inc. announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS).

• 

  Acadia and Stoke Team Up Against Neurodevelopmental Diseases

  1/10/2022

  ​The collaboration covers several neurodevelopmental targets, including Rett syndrome, SYNGAP1 syndrome, and one other disease yet to be disclosed. 

• Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Stoke Therapeutics, Inc. today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET.

• 

  Clinical Catch-Up: December 6-10

  12/13/2021

  There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
• 

  Trials Show Hope on the Horizon for Dravet Syndrome, Glioblastoma

  12/6/2021

  An investigational drug for Dravet syndrome is showing promise in treating the progressive form of genetic epilepsy.

• Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

  12/3/2021

  Stoke Therapeutics, Inc. today announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society (AES) 2021 Annual Meeting, December 3 – 7.

• Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting

  11/19/2021

  Stoke Therapeutics, Inc. today announced that five abstracts related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2021 Annual Meeting, taking place December 3 – 7, 2021 in Chicago.

• Stoke Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

  11/8/2021

  Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, reported financial results for the third quarter of 2021 and provided business updates.

• Stoke Therapeutics to Present at Upcoming Investor Conferences on November 10

  11/3/2021

  Stoke Therapeutics, Inc. today announced that management will present at two upcoming investor conferences in November.

• Stoke Therapeutics to Present at the Cantor Global Healthcare Virtual Conference

  9/22/2021

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Medical Officer Barry Ticho, M.D., Ph.D., will present at the Cantor Global Healthcare Virtual Conference.

• Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

  9/21/2021

  Stoke Therapeutics, Inc. announced positive safety, pharmacokinetic and cerebrospinal fluid exposure data from a planned interim analysis of the multi-center, open-label Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome.